key: cord-0740614-ktiawe1s
authors: Baig, Abdul Mannan
title: Correlating Biochemical and Structural Changes in the Brain with Clinical Features in COVID-19
date: 2022-04-02
journal: ACS Chem Neurosci
DOI: 10.1021/acschemneuro.2c00164
sha: c94678e1e25ddc6503e7e8e245cea5542f725852
doc_id: 740614
cord_uid: ktiawe1s

With emerging reports of the deleterious effects of SARS-CoV-2 reflecting as neurological deficits in COVID-19, the biochemical and morphological changes it casts on the brain are also being investigated. This is an important niche of research as it is expected to predict and relate the neurological clinical features in the acute phase and chronic syndromic forms of COVID-19. Here debated are the biochemical and structural changes that can be related to the neurological manifestations in COVID-19.

of normal to the near-normal brain and spinal cord scans ( Figure  1C ), there is a need to identify CSF biomarkers and serum markers (Figure 1 , top-right panel), that can hint toward an ongoing neuronal injury. Additional diagnostic modalities like nerve conduction studies, PET scans, and thorough clinical examination should be brought into consideration to include or exclude the neurological deficits in symptomatic COVID-19 patients with features of neurological damage.

Susceptibility of the Neurons to Cellular Injury and Routes to the Brain. Among the tissues and organs of the human body, the neurons that are the building blocks of the human central nervous system (CNS), and glial cells, are sensitive cells that succumb easily to diverse factors capable of causing cell damage like hypoxia, extremes of pH, toxic chemicals, and infectious organisms including viruses. Also, unlike other human tissues where a cellular loss is compensated by regeneration of identical cells by the stem cells, the human CNS mostly is devoid of stem cells; therefore a neuronal loss is a permanent event and mostly is replaced by gliosis. Given the sensitivity of the neurons and glia to injurious influences, evolutionarily the CNS has built the blood−brain barrier (BBB) to protect itself from damaging influences. The toxin and microbes that enter the CNS can adopt routes that can bypass the BBB. Examples include nerve gases and parasite pathogens like Naegleria fowleri. In COVID-19 the SARS-CoV-2 has been shown 5 to reach the brain via the cribriform plate of the ethmoid bone, 1,4,5 bypassing the BBB (Figure 1 A) .

Relating the Effects of Neuronal Injury to Syndromic Neuro-COVID. The knowledge of the functions of different areas of the brain has enabled us to relate the zone of neuronal damage to functional loss. In a patient who presents with signs and symptoms of neurological origin, a CT scan or MRI of a particular area of the brain can provide clues toward neuronal damages caused by either direct effects of the SARS-CoV-2 1,5 or diverse factors like hypoxia, inflammation, or cytokine-mediated injury. This correlation is not possible when the damage is ongoing at the molecular level and the changes sufficient to document an abnormality on CT scan or MRI are yet to be develop (Figure 1 C) , as has been the case with many patients with long-COVID in long-haulers who exhibit neurological features like "brain fog" and diminished cognitive functions.

Need for Investing in Biomedical Research in Neuro-COVID. To prevent damages to the neurons before they can cause fatality in COVID-19 or disability in long-COVID, it is important to invest in research that can identify biochemical markers (Figure 1 , top-right panel) that can be a clue toward an ongoing neuro-COVID in either acute phase or chronic syndromic form of COVID-19 as in the case of long-haulers. 5 Prevention of neuro-COVID by topical drug and vaccine delivery devices that can reduce the viral load in the nose 5 is also needed. The research on COVID-19 and the recently emerging long-COVID patients is in its infancy, and a huge investment in research is expected to find a resolution in the form of neurotropic antiviral agents or anti-inflammatory drugs that can cross the BBB and reduce inflammation and cytokine-mediated neuronal damage in long-COVID and COVID-19.

The neurological damages that have been reported in the current pandemic of COVID-19 are of concern not only because the CNS involvement in COVID can cause mortalities more than the similar intensity of infection in any other organ or tissue but also because of the concern of the disabilities expected in the patients who survive the acute phase of COVID-19. The latter is not a prediction but a fact, as this has been seen in long-COVID and long-haulers 5 that has now been recognized by WHO and CDC as a disease entity. Most of the patients with long-COVID are disabled due to particular or diffuse damage to the CNS as has been reported recently. After the first indication of the COVID-19 targeting the CNS via the nose, published in ACS Chemical Neuroscience, and the hints that the virus may opt for a pathway across the cribriform plate at the root of the nose to reach the olfactory pathways and brain, 1 the finding of mRNA of SARS-CoV-2 around the cribriform plate, olfactory bulb, and diverse regions of the brain 4 should have alerted us to anticipate the neurological damages in COVID-19. Similarly, this viewpoint is drawing attention toward a wide range of neurological deficits caused by SARS-CoV-2 in long-haulers and long-COVID. Immediate investment in form of funding research by the healthcare regulating bodies is needed to minimize the incidence of neurological deficits in long-COVID syndrome. Early detection by identification of biomarkers that hint neurological damage in COVID-19 is needed. Though scanrelated changes would prove to be of enormous value to study CNS damages in COVID-19, 3 prevention of irreversible neuronal and glial damage long before the loss of brain mass leading to changes in CT and MRI could prove to be one of the ways to contain neuro-COVID during this pandemic. The author declares no competing financial interest.

The author thanks the members of Long Covid-19 Foundation, U.K., for their discussions into diverse causes of long-COVID. This research has no funding resources.

Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms

The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients

SARS-CoV-2 is associated with changes in brain structure in UK Biobank. medRxiv 2022

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

Counting the neurological cost of COVID-19